Protein study aims to sharpen CLL diagnosis
NCT ID NCT07313982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a protein called LEF-1 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if measuring LEF-1 can help make a more accurate diagnosis and find new clues about the disease. They will study tissue samples from 350 adults already diagnosed with CLL/SLL.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better diagnostic tools and new markers to guide treatment for CLL/SLL patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change patient care or lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with SLL/CLL who turned to the Hemolymphatic Pathology Unit of the IRCCS - Bologna University Hospital, Policlinico S. Orsola-Malpighi, and the Hemolymphatic Pathology Unit of the Pathological Anatomy Unit, Policlinico Universitario Umberto I, Rome, from January 2014 to December 2024.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a confirmed diagnosis of SLL/CLL - B * Males and females, adults at diagnosis * Patients with available tissue (lymph node, extralymph node, or bone marrow) on which immunohistochemical analysis including LEF-1 has been performed and who have already submitted mutational and/or cytogenetic analysis data. Exclusion Criteria: * \- Patients with LEF1-positive indolent B-cell lymphomas not supported by a genetic evaluation with SSL/CLL. * CLL cases for which a biopsy is not available
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Irccs Azienda Ospedaliero-Universitaria Di Bologna
RECRUITINGBologna, BOLOGNA, 40138, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.